Study Comparing SOM230 Subcutaneously and Sandostatin Subcutaneously in Acromegalic Patients
Study Comparing SOM230 Subcutaneously and Sandostatin Subcutaneously in Acromegalic Patients
5 month study comparing SOM230 s.c. and Sandostatin s.c. in acromegalic patients.
Inclusion Criteria:

 -  Patients with active acromegaly due to a pituitary adenoma

 -  Patients who have been previously treated for acromegaly with certain medications may
 be required to be without certain medications prior to entering the study

 Exclusion Criteria:

 -  Patients with compression of the optic chiasm causing any visual field defect

 -  Patients who require a surgical intervention for relief of any sign or symptom
 associated with tumor compression

 -  Patients who have received radiotherapy in the 2 years prior to the start of the trial

 -  Patients who have congestive heart failure, unstable angina, cardia arrhythmia, or a
 history of acute myocardial infarction within the three months preceding enrollment

 -  Patients with gallstone disease

 -  Patients with chronic liver disease

 -  Known hypersensitivity to Sandostatin or Sandostatin LAR

 -  Female patients who are pregnant or lactating, or are of childbearing potential and
 not practicing a medically acceptable method of birth control and highly effective
 method for birth control

 -  History of immunocompromise, including a positive HIV test result

 -  Patients who have a history of alcohol or drug abuse in the six-month period prior to
 the enrollment visit

 -  Patients who have participated in any clinical investigation with an investigational
 drug within 4 weeks prior to dosing